Ratings Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-17 pm EDT			5-day change	1st Jan Change
5.07 ^USD	+0.20%		-4.70%	-49.95%

Jun. 14	Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial	MT
Jun. 14	Editas Medicine Announces New Safety and Efficacy Data from the Edithal Trial of Reni-Cel in 7 Patients with Transfusion-Dependent Beta Thalassemia, Presented At the European Hematology Association Annual Congress	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
EDITAS MEDICINE, INC.	-49.95%	416M	C+
MODERNA, INC.	+38.66%	53.67B	B-
LONZA GROUP AG	+33.67%	38.86B	A
IQVIA HOLDINGS INC.	-7.81%	38.76B	B
CELLTRION, INC.	-10.77%	27.27B	C
ICON PUBLIC LIMITED COMPANY	+11.77%	25.91B	B-
ALNYLAM PHARMACEUTICALS, INC.	-17.82%	20.29B	B
UNITED THERAPEUTICS CORPORATION	+35.09%	12.78B	B+
MEDPACE HOLDINGS, INC.	+29.17%	12.18B	C+
BIO-TECHNE CORPORATION	-3.05%	11.96B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes